Proteins and Peptides

27 Sep 2007 Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
27 Sep 2007 Cytheris Expands Interleukin-7 Clinical Development Program With International Phase I/IIa Trial In HIV
27 Sep 2007 New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
27 Sep 2007 OctoPlus in-licenses diabetes product candidate
25 Sep 2007 Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
25 Sep 2007 European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
25 Sep 2007 Pacgen Announces Advances in PAC-113 Program
22 Sep 2007 ThromboGenics Completes Enrolment of Patients for the Vitreomacular Traction Trial (MIVI IIT)
22 Sep 2007 Maxygen Announces Hold on MAXY-alpha Development Program
22 Sep 2007 One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
21 Sep 2007 Acceleron Pharma's ACE-011 Increases Bone Mineral Density and Bone Strength in Primate Studies
21 Sep 2007 Novo Nordisk receives approval in the EU for use of NovoRapid(R) in elderly people
20 Sep 2007 Zelos Therapeutics Presents Positive Data at ASBMR on Subcutaneous and Inhaled Delivery of Cyclic PTH (1-31) (Ostabolin-C(TM))
20 Sep 2007 Teva Provides Update on Edratide for Systemic Lupus Erythematosus
19 Sep 2007 New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
19 Sep 2007 Sinobiomed Updates on Clincial Trial Success for Recombinant Batroxobin (rBat)
19 Sep 2007 Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation
18 Sep 2007 A major pharmaceutical company has taken an exclusive option to BA058, a compound licensed by Ipsen to Radius in 2005
18 Sep 2007 SYGNIS' AX200 shows efficacy in stroke patients
15 Sep 2007 Novartis completes agreement with Bayer Schering related to Betaseron(R) rights and manufacturing
15 Sep 2007 Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events
14 Sep 2007 Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study
14 Sep 2007 FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol
13 Sep 2007 Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
12 Sep 2007 Phosphagenics to commence Phase 2 TPM/Insulin cinical trial

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top